Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sirolimus

FDA-approved product (solution, oral), marketed as Fyarro, Hyftor, Rapamune and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenoma sebaceum
  • Angiofibroma
  • Cancer
  • Delayed Graft Function
  • Eye disease
  • Kidney transplant
  • Neoplasm
  • Tuberous sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors; Other ophthalmologicals
FDA pharmacologic class
Kinase Inhibitor; mTOR Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

    NCT02959918 · start 2016-10

    Registered record
    Registry ID
    NCT02959918
    Conditions
    Gout Chronic; Hyperuricemia
    Interventions
    SEL-212; SEL-037; SVP-rapamycin (SEL-110)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2019-01
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout Chronic; Hyperuricemia
    InterventionSEL-212; SEL-037; SVP-rapamycin (SEL-110)
    PhasePhase 2
    Registry statusCompleted

  • Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

    NCT02960997 · start 2016-05

    Registered record
    Registry ID
    NCT02960997
    Conditions
    Epidermolysis Bullosa Simplex; Epidermolysis Bullosa Simplex Kobner; Weber-Cockayne Syndrome
    Interventions
    Sirolimus, 2%; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2021-12-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpidermolysis Bullosa Simplex; Epidermolysis Bullosa Simplex Kobner; Weber-Cockayne Syndrome
    InterventionSirolimus, 2%; Vehicle
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

    NCT02531932 · start 2015-12-16

    Registered record
    Registry ID
    NCT02531932
    Conditions
    Breast Cancer
    Interventions
    Carboplatin; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-16
    Completion
    2024-10-19
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionCarboplatin; Everolimus
    PhasePhase 2
    Registry statusCompleted

  • PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

    NCT02584647 · start 2015-11-04

    Registered record
    Registry ID
    NCT02584647
    Conditions
    Sarcoma; Malignant Peripheral Nerve Sheath Tumors
    Interventions
    PLX3397; sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-11-04
    Completion
    2024-10-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma; Malignant Peripheral Nerve Sheath Tumors
    InterventionPLX3397; sirolimus
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    NCT02356159 · start 2015-09-24

    Registered record
    Registry ID
    NCT02356159
    Conditions
    Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
    Interventions
    Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2025-03-25
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 more
    InterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

    NCT02042326 · start 2014-09-12

    Registered record
    Registry ID
    NCT02042326
    Conditions
    Arteriovenous Malformations
    Interventions
    Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-09-12
    Completion
    2027-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArteriovenous Malformations
    InterventionSirolimus
    PhasePhase 2
    Registry statusRecruiting

  • Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

    NCT02029001 · start 2014-03

    Registered record
    Registry ID
    NCT02029001
    Conditions
    Malignant Solid Neoplasms
    Interventions
    Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD); Olaparib (300 mg BID); Durvalumab + Tremelimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-03
    Completion
    2028-10
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Solid Neoplasms
    InterventionNilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD) +3 more
    PhasePhase 2
    Registry statusRecruiting

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Topical Rapamycin to Erase Angiofibromas in TSC

    NCT01526356 · start 2012-05

    Registered record
    Registry ID
    NCT01526356
    Conditions
    Angiofibromas; Tuberous Sclerosis
    Interventions
    Placebo; Rapamycin; Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-08
    Enrolment
    179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngiofibromas; Tuberous Sclerosis
    InterventionPlacebo; Rapamycin; Rapamycin
    PhasePhase 2
    Registry statusCompleted

  • Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

    NCT01582048 · start 2012-04

    Registered record
    Registry ID
    NCT01582048
    Conditions
    Patients Receiving Mismatched Allogeneic HCT
    Interventions
    immunosuppression
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-04
    Completion
    2016-08-17
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Receiving Mismatched Allogeneic HCT
    Interventionimmunosuppression
    PhasePhase 2
    Registry statusTerminated

  • Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease

    NCT01443754 · start 2011-09

    Registered record
    Registry ID
    NCT01443754
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    LIMA-LAD surgical revascularization; PCI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionLIMA-LAD surgical revascularization; PCI
    PhaseNot recorded
    Registry statusTerminated

  • Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

    NCT01332279 · start 2011-04

    Registered record
    Registry ID
    NCT01332279
    Conditions
    Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer
    Interventions
    everolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis; immunohistochemistry staining method; polyacrylamide gel electrophoresis; pharmacological study; external beam radiation therapy; microarray analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx +7 more
    Interventioneverolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis +5 more
    PhasePhase 1
    Registry statusWithdrawn

  • Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

    NCT01264341 · start 2010-12

    Registered record
    Registry ID
    NCT01264341
    Conditions
    Kidney Cancer
    Interventions
    Bevacizumab; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2015-07
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    InterventionBevacizumab; Temsirolimus
    PhasePhase 2
    Registry statusTerminated

  • A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

    NCT01369433 · start 2010-06

    Registered record
    Registry ID
    NCT01369433
    Conditions
    Solid Tumors
    Interventions
    Tivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951); Tivozanib + capecitabine; Tivo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-06
    Completion
    2015-10
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionTivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951) +2 more
    PhaseNot applicable
    Registry statusTerminated

  • Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

    NCT01150097 · start 2010-03-31

    Registered record
    Registry ID
    NCT01150097
    Conditions
    Liver Transplant Recipient
    Interventions
    Tacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination); Tacrolimus (tacrolimus control); Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03-31
    Completion
    2013-05-03
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant Recipient
    InterventionTacrolimus (reduced tacrolimus); Everolimus (reduced tacrolimus); Tacrolimus (tacrolimus elimination); Everolimus (tacrolimus elimination) +2 more
    PhasePhase 3
    Registry statusCompleted